Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis-Reference-Cited by-同舟云学术

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis

Published:2018-04-03 Issue:4 Volume:36 Page:732-741
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Kang Jihoon,Hwang Inhwan,Yoo Changhoon,Kim Kyu-pyo,Jeong Jae Ho,Chang Heung-Moon,Lee Sang Soo,Park Do Hyun,Song Tae Jun,Seo Dong Wan,Lee Sung Koo,Kim Myung-Hwan,Hong Seung-Mo,Shin Sang Hyun,Hwang Dae Wook,Song Ki Byung,Lee Jae Hoon,Kim Song Cheol,Ryoo Baek-Yeol

Funder

Asan Institute for Life Sciences, Asan Medical Center

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/article/10.1007/s10637-018-0598-5/fulltext.html

Reference22 articles.

1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C et al (2017) Global, regional, and National Cancer Incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 Cancer groups, 1990 to 2015. JAMA Oncol 3:524–525. https://doi.org/10.1001/jamaoncol.2016.5688

2. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387

3. Jung K-W, Won Y-J, Oh C-M, Kong HJ, Lee DH, Lee KH, The Community of Population-Based Regional Cancer Registries (2017) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 49:292–305. https://doi.org/10.4143/crt.2017.118